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Although inherited mitochondrial genetic variation can cause human disease, no validated methods exist for control of confounding
due to mitochondrial population stratiﬁcation (PS). We sought to identify a reliable method for PS assessment in mitochondrial medical
genetics. We analyzed mitochondrial SNP data from 1513 European American individuals concomitantly genotyped with the use of
a previously validated panel of 144 mitochondrial markers as well as the Affymetrix 6.0 (n ¼ 432), Illumina 610-Quad (n ¼ 458), or
Illumina 660 (n ¼ 623) platforms. Additional analyses were performed in 938 participants in the Human Genome Diversity Panel
(HGDP) (Illumina 650). We compared the following methods for controlling for PS: haplogroup-stratiﬁed analyses, mitochondrial prin-
cipal-component analysis (PCA), and combined autosomal-mitochondrial PCA. We computed mitochondrial genomic inﬂation factors
(mtGIFs) and test statistics for simulated case-control and continuous phenotypes (10,000 simulations each) with varying degrees of
correlation with mitochondrial ancestry. Results were then compared across adjustment methods. We also calculated power for
discovery of true associations under each method, using a simulation approach. Mitochondrial PCA recapitulated haplogroup informa-
tion, but haplogroup-stratiﬁed analyses were inferior to mitochondrial PCA in controlling for PS. Correlation between nuclear and
mitochondrial principal components (PCs) was very limited. Adjustment for nuclear PCs had no effect on mitochondrial analysis of
simulated phenotypes. Mitochondrial PCA performed with the use of data from commercially available genome-wide arrays correlated
strongly with PCA performed with the use of an exhaustive mitochondrial marker panel. Finally, we demonstrate, through simulation,
no loss in power for detection of true associations with the use of mitochondrial PCA.Introduction
Sequence variants within the mitochondrial genome have
been extensively investigated for association with medical
conditions,1–3 given the central role of mitochondria in
energy metabolism and cell survival.4–6 Population stratiﬁ-
cation (PS), the phenomenon by which variation in minor
allele frequency (MAF) due to ancestry inﬂuences associa-
tion with medical phenotypes of interest, is a common
confounder in genetic-association studies.7 Although
several tools have been developed to adjust for genetic
ancestry in autosomal GWAS,8 the efﬁciency and effective-
ness of different PS adjustment methods for mitochondrial
genetic-association studies have not been empirically
evaluated.
Adequate control for PS is crucial for mitochondrial
medical genetics, given the large inﬂuence of ancestry
and genealogy on the MAF of mitochondrial variants. In
fact, all common variants in the mitochondrial genome
possess some degree of information on genetic ancestry.9
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structure.10 This approach restricts generalizability of
results to individuals carrying the analyzed haplogroup,
thereby limiting its applicability to the ﬁeld of common
disease genetics. Other approaches have relied on case-
control matching for geographic origin.6,11 This method
capitalizes on an assumed association between mitochon-
drial haplogroups and geography within continents.
However, neither of these methods has ever been tested
against any alternatives, particularly with respect to efﬁ-
ciency (retention of statistical power after adjustment)
and effectiveness (reduction in proportion of false-positive
results generated after adjustment).
We sought to evaluate the effectiveness and efﬁciency
of different methods of PS assessment in mitochondrial
medical genetics by using both autosomal (from commer-
cial GWAS platforms) and mitochondrial (from compre-
hensive genotyping) genome-wide data provided by
investigators within the International Stroke Genetics
Consortium (ISGC). We compared the utility of mito-
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haplogroup-based adjustment in association tests of mito-
chondrial variants. Furthermore, given the correlation
between autosomal population structure and geog-
raphy,12,13 we hypothesized that genome-wide autosomal
data might assist in adjustment for mitochondrial PS. We
therefore evaluated effectiveness and efﬁciency of com-
bined mitochondrial-autosomal PCA (compared to mito-
chondrial PCA only) in adjusting for confounding due to
mitochondrial PS. Finally, we investigated whether consis-
tent PCA results could be obtained with the use of compre-
hensive mitochondrial genotyping or mitochondrial vari-
ants captured by commercially available GWAS platforms.Subjects and Methods
Samples
Samples were contributed by the Massachusetts General Hospital
Ischemic Stroke GWAS (MGH-AIS),14 by the Massachusetts
General Hospital Intracerebral Hemorrhage Stroke GWAS
(MGH-ICH),15 and by investigators participating in the Ischemic
Stroke Genetics Study (ISGS)16 and the Siblings With Ischemic
Stroke Study (SWISS).17 MGH-AIS GWAS samples were genotyped
on the Affymetrix 6.0 platform (n ¼ 432), MGH-ICH samples
(n ¼ 458) on the Illumina 610-Quad platform, and ISGS-SWISS
samples (n ¼ 623) on the Illumina 660 platform. All institutional
review boards of participating institutions approved the aforemen-
tioned studies, and all participants gave written informed consent
for participation. In order to compare results from our US cohorts
with those from European and non-European individuals, we
analyzed individuals genotyped as part of the Human Genome
Diversity Panel (HGDP) and obtained from publicly available
resources.18,19 The HGDP comprises 938 unrelated individuals
successfully genotyped (call rate > 98.5%) on Illumina Human-
Hap650K Beadchips, representing 51 population groups in every
continent but Antarctica.20 Detailed information on participating
studies and populations is presented in Table 1.
Comprehensive Genotyping of Mitochondrial
Common Variants
Mitochondrial common variants were genotyped according to a
published protocol.2 In brief, we identiﬁed all 144 variants with
frequency > 1% in Europeans from > 900 publicly available
European mtDNA sequences and selected 64 tagging SNPs that
efﬁciently capture all common variation (except the hypervariable
D-loop). Genotyping was performed on the Sequenom platform
(San Diego, CA, USA).
Imputation was performed for identiﬁcation of the pre-HV, H1,
H2, J, K, T, U, WX, and I haplogroups in all samples in accordance
with previously published methods.21 In brief, a total of 1074
complete sequences from the ten most common European
haplogroups (H, I, J, K, M, T, U, V, W, and X) were downloaded
from mtDB. From these sequences, the genotypes at tagging-SNP
loci were determined and used as predictors in a linear discrimi-
nant function analysis in the R v 2.10.0 statistical package. The
accuracy of haplogroup prediction was determined via a bootstrap
crossvalidation approach. For each of 1000 replicates, a bootstrap
sample of sequences was chosen to form the prediction model,
and the unsampled sequences had their haplogroups predicted.
The prediction accuracy was then determined simply as the
proportions of sequences whose haplogroups were correctly pre-The Amedicted. In line with previously reported results,21 95% of all cross-
validation replicates had a prediction accuracy of > 98.5%.
Population-Structure Assessment
We performed PCA separately (methods detailed below) on mito-
chondrial and autosomal SNP data to determine genetic ancestry
and to compare information on population structures between
the autosomal and mitochondrial genomes.22–24 We extracted
the ﬁrst ten principal components (PCs) for both mitochondrial
and autosomal data and assessed all possible correlations by
computing Spearman’s correlation coefﬁcients. We also evaluated
the relationship between haplogroups (as determined by exhaus-
tive mitochondrial SNP data) and population structure. Speciﬁ-
cally, correlation coefﬁcients (Spearman) were calculated for
correlations between haplogroup assignments and PCs (both auto-
somal and mitochondrial).Autosomal Genome PCA
For both Illumina and Affymetrix genome-wide data sets, nuclear
genomic population structure was assessed by the performance of
PCA with the use of the EIGENSTRAT program in the EIGENSOFT
v 3.0 software package.23,24 Analyses were performed separately
via the multidimensional scaling (MDS) procedure implemented
in PLINK v 1.07.25 Results from separate analyses performed
with these two software tools were then compared and found to
be highly correlated (correlation coefﬁcient > 0.99).
Nuclear PCAs were performed on a subset of all SNPs selected
with the use of the following criteria: percentage of missing geno-
types < 0.001, MAF > 0.05, and Hardy-Weinberg equilibrium
(HWE) p value > 0.0001. For the avoidance of confounding due
to linkage disequilibrium (LD), only SNPs with r2 < 0.2 with all
other SNPs within a 1 Mb sliding window (sliding: 250 Kb) were
entered into the PCA. Furthermore, we removed SNPs in known
extensive regions of LD (chromosome [chr.] 5: 44–51.5 Mb; chr.
6: 25–33.5 Mb; chr. 8: 8–12 Mb; chr. 11: 45–57 Mb),26 as well as
all mitochondrial SNPs.
We assigned genotype-determined ancestry by performing PCA
on study subjects and reference populations fromHapMap Phase 3
data: CEU (European-ancestry residents of UT, USA), TSI (Tuscans
in Italy), MEX (Mexicans in Los Angeles, CA, USA), CHD (Chinese
in Denver, CO, USA), and ASW (African Americans and individ-
uals from Southwestern USA). As a measure of controlling for PS,
only individuals clustering with CEU and/or TSI populations
were considered to be of European ancestry. Clustering-inferred
genetic ancestry was compared with haplogroup-determined
ancestry. We subsequently reclustered European-ancestry individ-
uals by using the same criteria and procedures and compared
results with those of mitochondrial PCA.Mitochondrial Genome PCA
We assessed mitochondrial population structure by performing
PCA on all SNPs genotyped to capture mitochondrial common
genetic variation, after applying ﬁlters for genotype missingness
< 0.10 and MAF > 0.01. We performed sensitivity analyses to
identify possible confounding effects of LD on ancestry determi-
nation, but we found that different LD-pruning criteria did not
alter PCA results signiﬁcantly (all PC correlations across different
sensitivity analyses> 0.95, p< 0.0001). Furthermore, we observed
that mitochondrial PCs (mtPCs) returned for PCA performed with
the use of the 64 tagging SNPs and the full panel of 144 SNPs were
highly concordant (all PC correlations > 0.99, p < 0.0001).rican Journal of Human Genetics 86, 904–917, June 11, 2010 905
Table 1. Participating Studies and Populations
Study No. of Samples Continent Population
Geographical
Location
Mitochondrial
Genotyping
Autosomal
Genotyping
MGH-AIS 432 American European American USA Comprehensive panel /
Affymetrix 6.0
Affymetrix 6.0
MGH-ICH 458 American European American USA Comprehensive panel /
Illumina 610
Illumina 610
ISGS-SWISS 623 American European American USA Comprehensive panel /
Illumina 660
Illumina 660
HGDP 157 Europe French France Illumina 650 Illumina 650
Sardinian Italy (Sardinia) Illumina 650 Illumina 650
Orcadian Orkney Islands Illumina 650 Illumina 650
Russian Russia Illumina 650 Illumina 650
Northern Italian Italy (Lombardy) Illumina 650 Illumina 650
Central Italian Italy (Tuscany) Illumina 650 Illumina 650
Basque Spain Illumina 650 Illumina 650
Adygei Caucasus Illumina 650 Illumina 650
HGDP 64 America Colombian Colombia Illumina 650 Illumina 650
Surui Brazil Illumina 650 Illumina 650
Maya Mexico Illumina 650 Illumina 650
Kairitiana Brazil Illumina 650 Illumina 650
Pima Mexico Illumina 650 Illumina 650
HGDP Africa Mbuti-Pigmy Congo Illumina 650 Illumina 650
Biaka-Pigmy Central African Republic Illumina 650 Illumina 650
Mandenka Senegal Illumina 650 Illumina 650
Yoruba Nigeria Illumina 650 Illumina 650
San Namibia Illumina 650 Illumina 650
Bantu Lesotho / Botswana Illumina 650 Illumina 650
Bantu South Africa Illumina 650 Illumina 650
Bantu Kenya Illumina 650 Illumina 650
HGDP Asia (Central / South) Brahui Pakistan Illumina 650 Illumina 650
Balochi Pakistan Illumina 650 Illumina 650
Hazara Pakistan Illumina 650 Illumina 650
Makrani Pakistan Illumina 650 Illumina 650
Sindhi Pakistan Illumina 650 Illumina 650
Pathan Pakistan Illumina 650 Illumina 650
Kalash Pakistan Illumina 650 Illumina 650
Burush Pakistan Illumina 650 Illumina 650
Uygur China Illumina 650 Illumina 650
HGDP 228 Asia (Eastern) Cambodian Cambodia Illumina 650 Illumina 650
Japanese Japan Illumina 650 Illumina 650
Jakut Siberia Illumina 650 Illumina 650
Han China Illumina 650 Illumina 650
Tujia China Illumina 650 Illumina 650
Chin China Illumina 650 Illumina 650
906 The American Journal of Human Genetics 86, 904–917, June 11, 2010
Table 1. Continued
Study No. of Samples Continent Population
Geographical
Location
Mitochondrial
Genotyping
Autosomal
Genotyping
Yi China Illumina 650 Illumina 650
Miao China Illumina 650 Illumina 650
Oroqen China Illumina 650 Illumina 650
Daur China Illumina 650 Illumina 650
Mongolian China Illumina 650 Illumina 650
Hezhen China Illumina 650 Illumina 650
Xibo China Illumina 650 Illumina 650
Dai China Illumina 650 Illumina 650
Lahu China Illumina 650 Illumina 650
She China Illumina 650 Illumina 650
Naxi China Illumina 650 Illumina 650
Tu China Illumina 650 Illumina 650
HGDP 163 Asia (Middle East) Druze Israel (Carmel) Illumina 650 Illumina 650
Bedouin Israel (Negev) Illumina 650 Illumina 650
Palestinian Israel (Central) Illumina 650 Illumina 650
Mozabite Algeria (Mzab) Illumina 650 Illumina 650
HGDP 27 Oceania Papuan New Guinea Illumina 650 Illumina 650
Melanesian Bougainville Illumina 650 Illumina 650
HGDP, Human Genome Diversity Panel; MGH-AIS, Massachusetts General Hospital Ischemic Stroke Study; MGH-ICH, Massachusetts General Hospital Intracere-
bral Hemorrhage Study; ISGS, Ischemic Stroke Genetics Study; SWISS, Siblings With Ischemic Stroke Study.The effect of each SNP on PCA was evaluated by removing
it from the list of markers determining genetic ancestry and
comparing analyses using this modiﬁed adjustment with the
full SNP-panel PC-adjusted analysis. We observed no differences
when comparing these different analytical procedures for
all mitochondrial SNPs (all correlation coefﬁcients > 0.99, all
p values < 0.0001).Controlling for Confounding Due to PS
We compared three different methods for mitochondrial PS
control: haplogroup-based stratiﬁed analysis, mitochondrial
PCA, and combined autosomal-mitochondrial PCA. To do so, we
generated 10,000 iterations of both case-control and quantitative
trait locus (QTL) phenotypes. These phenotypes were generated to
simulate the null hypothesis (i.e., no association with any mito-
chondrial variant) and to display varying degrees of correlation
withmtPC1, with the following Spearman correlation coefﬁcients:
0.00, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60.
For phenotype simulation, available samples within each data
set were grouped into deciles on the basis of their mtPC1 values.
In case-control simulation, an unsupervised algorithm randomly
generated ten increasing probability values (p1–p10), ranging
from 0.0 to 1.0, and assigned them to individuals in each mtPC1
decile group. Each individual was then assigned a random proba-
bility value, prand, ranging from 0.0 to 1.0 and based on random
number generation. Individuals in mtPC1 decile i (with i ranging
from 1 to 10) with prand> piwere deﬁned as cases, and the remain-
ing individuals were deﬁned as controls. Simulated phenotypesThe Amethat were generated by this algorithm and met the required
correlation criteria with mtPC1 (tolerance:5 2.5%), were retained
for in silico association testing, and the remainder were discarded.
For QTL phenotypes, the unsupervised algorithm identiﬁed
for each individual u, such that: 4 ¼ r,mtPC1þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 r2
p
,u, in
which 4 is the desired QTL phenotype value and r is the desired
Spearman’s correlation coefﬁcient. As for case-control simula-
tions, phenotypes that met correlation criteria with mtPC1 (toler-
ance:5 2.5%) were retained for in silico association testing.
Quality-control checks were performed for the elimination of
simulated phenotypes that (1) were perfect duplicates (case-
control status or QTL values identical for all subjects) of previously
generated phenotypes; (2) did not achieve a case:control ratio of
1.05 0.05 (for case-control simulations); 3) displayed nonnormal
distributions, as identiﬁed by p < 0.05 for the Shapiro-Wilk
normality test (for QTL phenotypes); and (4) displayed signiﬁcant
associations with any mitochondrial variant. For this quality-
control ﬁlter, signiﬁcant associations were deﬁned as those return-
ing p values beating the Bonferroni multiple-testing correction for
144 independent tests, i.e., p < 0.00035. Additional analyses
removing phenotypes at a more lenient threshold imposed by
counting only tagging SNPs as independent tests (p < 0.0008)
did not alter results (data not shown).
We also performed sensitivity analyses by generating similarly
stratiﬁed phenotypes, both case-control and QTL, according to
mtPCs 2–10 and to haplogroup assignment and compared results.
Phenotype generation for mtPCs 2–10 was identical to methods
described above. For haplogroups, an unsupervised algorithm
randomly generated case-control (random sampling fromrican Journal of Human Genetics 86, 904–917, June 11, 2010 907
binomial distribution) or QTL (random normally distributed vari-
able generation) phenotypes. For all generated phenotypes,
logistic or linear regression was performed, with age, sex, and
haplogroup assignment (multilevel categorical covariate) as
predictors. Phenotypes displaying association with one or more
haplogroups at p < 0.05 and passing previously described
quality-control checks were retained for analysis.
Both autosomal PCs and mtPCs were entered as covariates in
logistic- or linear-regression models for PS. We entered additional
PCs until no further reduction of the empirical estimate of the
mtGIF (see below) could be achieved. Autosomal PCs and mtPCs
were entered separately in the combined PCA method analyses,
and their impact on mtGIF was assessed independently. Hap-
logroup-based PS control was achieved with the use of three
different analytical strategies: (1) regression analyses were per-
formed within strata deﬁned by each haplogroup, with the use
of either the Cochran-Mantel-Haenszel test (case-control) or the
combination of results from a Z-score-based (Liptak-Stouffer)
method (QTL); (2) haplogroup assignment was introduced in
regression analyses as a categorical multilevel covariate, with the
average effect across all categories assumed as reference for compu-
tation of effect sizes; (3) regression analyses were performedwithin
each haplogroup and combined with the use of a random-effects
inverse-variance-weighted metaanalysis (DerSimonian-Laird
method). Heterogeneity metrics27 were computed for the assess-
ment of uniformity of effect sizes comparing haplogroups: specif-
ically, we computed the heterogeneity Q statistic (and associated p
value) and I2, i.e., the proportion of effect size attributable to
between-study heterogeneity. We deﬁned signiﬁcant heteroge-
neity as p < 0.10 (because of the underpowered nature of the
Cochrane heterogeneity test) and I2 > 0.20.27
Effectiveness of PS control was assessed by computing mito-
chondrial genomic inﬂation factors (mtGIFs) for all analyses. As
for the GIF in GWAS,28 the mtGIF was computed by dividing the
median observed test statistic (as returned by association testing
with the use of different PS-adjustment methods) by the expected
test statistic under the null. The mtGIF was computed for each
simulation, and values from each analytical scenario were
grouped, thus yielding an empirical estimate and 95% conﬁdence
interval of mitochondrial genomic inﬂation. MtGIF distributions
for different adjustment methods were compared with the use of
an ANOVA (followed by Tukey’s post hoc test) or the Wilcoxon-
Mann-Whitney test, as appropriate.
Comparison of Mitochondrial PCA Derived from
Commercial Arrays and Comprehensive Genotyping
Using 10,000 simulated stratiﬁed case-control and QTL pheno-
types exhibiting varying degrees of correlationwithmtPC1 (gener-
ated via methods described above), we performed mitochondrial
PCA, using comprehensive genotyping data as well as mitochon-
drial SNP data derived from Affymetrix 6.0 or Illumina 610-Quad
for the same subjects. Mitochondrial PCA on array data was
performed with the use of identical quality-control ﬁlters and
procedures as those described above. SNPs available for mitochon-
drial PCA for each tested platform are listed in Tables S1 and S2,
available online. We also used previously described methods to
assign haplogroups to individuals, using commercial array data.
All major European haplogroups (H, JT, UK) could be assigned
on the basis of available SNPs, as could major African (L, L1, L2,
L3) and Asian (A, D) haplogroups.
After adjustment for mitochondrial PCA results, we then
compared test statistics and mtGIF between comprehensive908 The American Journal of Human Genetics 86, 904–917, June 11,genotyping and Affymetrix 6.0 (MGH-AIS), as well as between
comprehensive genotyping and Illumina 610-Quad (MGH-ICH
and ISGS-SWISS). We also measured correlation coefﬁcients
between these two sets of results to examine the consistency of
PCA adjustment between the two platforms.
Statistical Power
To compare the efﬁciency of different mitochondrial PS tools on
statistical power for discovery of true association, we performed
simulations according to a previously published and validated
method for power calculation of mitochondrial common vari-
ants.21 In brief, we generated case-control and QTL phenotypes
displaying association with each of the 144 SNPs in the total
combined data set obtained by merging MGH-AIS, MGH-ICH,
and ISGS-SWISS studies (n ¼ 1513). We performed 10,000 simula-
tions for each SNP, separately assessing case-control and QTL
phenotypes. This yielded a total of 2,880,000 simulations
(10,000 3 144 SNPs 3 2 analytical scenarios). For case-control
simulations, power was calculated for a SNP-conferred relative
risk of 1.2, 1.5, and 2.0 at a sample size of 500, 1000, 1500, and
3000 case-control pairs. For QTL analyses, we estimated power
for discovery of a SNP-related effect explaining 0.25%, 0.5%, and
1% of the total trait variance for sample sizes of 500, 1000,
1500, and 3000 samples.
In the case-control setting, the control pool was generated by
random selection of samples with replacement from the 1513
individuals in order to achieve the desired sample size. For the
case pool, MAF at the causal SNP was determined on the basis of
genetic relative risk (GRR). Assuming that the disease under
study is rare, GRR at a mitochondrial locus can be expressed as
GRR z (pcases(1  pcontrols)) / (pcontrols(1  pcases)), in which
pcontrols is the allele frequency in controls and pcases is the
frequency in cases. With the use of the calculated MAF in cases,
the number of individuals with each allele at the causal SNP is
determined with the use of a random draw from a binomial distri-
bution. The case sample is then generated by sampling with
replacement from the subset of individuals with the relevant allele
at the causal SNP in order to achieve the previously determined
number of samples with each allele.
The power to detect a locus affecting a quantitative trait was
examined by randomly drawing a sample of individuals with
replacement. A quantitative trait was then simulated by calcu-
lating the required effect at the causal SNP through rearranging
the formula sa
2 ¼ p(1  p)a2, in which sa2 is the genetic variance
explained by the causal SNP, p is the allele frequency at that SNP,
and a is the effect of the SNP in phenotypic standard-deviation
units. Genetic variance explained bymitochondrial variants repre-
sents half the value of an autosomal locus with the same additive
effect and MAF, due to the haploid nature of the mitochondria.
Because the samples are considered to be unrelated, the remaining
phenotypic variance was simulated as random normal deviations.
The effect of each SNP was tested with the use of logistic regres-
sion in the case-control setting and linear regression for QTL traits.
All analyses were adjusted for age and sex. Signiﬁcance was deter-
mined at the 0.05 experiment-wide level, deﬁned with the use of
a threshold obtained with 10,000 simulation replicates under
the null hypothesis. We also calculated the noncentrality param-
eter for all tests; i.e., the difference in the mean of the distribution
of the log10 of the minimum p value across all SNPs under the
alternative and null hypotheses. Statistical power for discovery
of simulated association was then compared across different
adjustment methods, both at the single-SNP level and the2010
Figure 1. Autosomal Population Struc-
ture for the MGH-AIS Study
Population structure of the MGH-AIS
subjects (black dots), based on autosomal
PCs 1 and 2, compared with reference pop-
ulations from Phase 3 of the HapMap
Project. CEU (red dots): residents of North-
western European ancestry residing in
Utah, US; TSI (green dots): Tuscans in Italy;
ASW (yellow dots): African Americans in
Southwestern USA; MEX (gray dots): Mexi-
cans in Mexico City; CHB (purple dots):
Han Chinese in Beijing.whole-mitochondrial-panel level, with the use of an ANOVA and
Tukey’s post-hoc test (where appropriate).
Mitochondrial Stroke Genetics
To conﬁrm the utility of an efﬁcient and effective method for PS
control in mitochondrial medical genetics, we analyzed data
collected as part of the MGH-AIS (660 cases and 749 controls of
European American ancestry). All participants were recruited at
a single institution in the USA (MGH, Boston, MA) with the use
of previously described enrollment and exclusion criteria.14
Clinical diagnosis of ischemic stroke (supported by neuroimaging
at admission) was the deﬁning criterion for case-control assign-
ment. Results surpassing the mitochondrial genome-wide
threshold for signiﬁcance (p < 0.05 after Bonferroni adjustment
for 144 independent tests) were further investigated in the ISGS-
SWISS data set, comprising 602 cases and 444 controls enrolled
in a multicenter genetic study of ischemic stroke, with identical
enrollment procedures followed.16 Statistical power for replication
was computed with the use of previously described methods
assuming a ¼ 0.05 and effect size and MAF observed in the
discovery analysis.
All samples were genotyped with the use of the exhaustive panel
mentioned in the ‘‘Comprehensive Genotyping of Mitochondrial
Common Variants’’ section.2 A subset of enrolled individuals in
each study were also genotyped on genome-wide arrays (Affyme-
trix 6.0 for MGH-AIS or Illumina 610 Quad for ISGS-SWISS) and
have been used in all previous analyses. We computed mtGIF
and test-statistic concordance for unadjusted analysis, hap-
logroup-adjusted analysis, and mitochondrial PCA as described
above. For haplogroup-adjusted analyses, results are reported
only for the approach returning the lowest mtGIF of the three
tested (see above).Results
PCA of Autosomal and Mitochondrial Genomes
We ﬁrst examined the information on population struc-
ture yielded by the mitochondrial genome and comparedThe American Journal of Humanit with that reﬂected in the autosomal
genome. Ancestry information in the
mitochondrial genome was extracted
in two ways: traditional halplogroup
assignments and PCA. We hypothe-
sized that PCA could be applied to
the mitochondrial genome as well
and could provide a reliable, easilyapplicable method for dissection of mitochondrial
ancestry, in a manner similar to its application in recent
GWAS.
Haplogroup assignment and ancestry assignment ac-
cording to PCA of the autosomal genome did not consis-
tently correlate. As expected from prior studies of PCA
analyses for the nuclear genome in European American
populations,22 the MGH-AIS cohort of US individuals is
composed mainly of subjects of European ancestry (clus-
tering with the CEU and TSI samples), with a minority of
samples being of African American (clustering with
ASW), Mexican American (clustering with MEX), and
Chinese American (clustering with CHB) origins (Figure 1).
Comparison with mitochondrial haplogroup information
in this cohort conﬁrms that individuals of African Amer-
ican and Chinese American ancestry are efﬁciently identi-
ﬁed by the African and Asian haplogroups (correlation
coefﬁcient¼ 0.99, p< 0.0001). In contrast, Mexican Amer-
ican ancestry could not be efﬁciently resolved on the basis
of haplogroup (Figure 2A). There was no correlation
between autosomal PCs and haplogroups when individ-
uals of European ancestry were analyzed (Figure 2B, all p
values > 0.20). Identical results emerged from analysis of
the MGH-ICH and ISGS-SWISS cohorts (data not shown).
PCA of the mitochondrial genome recapitulated the
population structure reﬂected in haplogroup assignment
(Figures 3A and 3B), with haplogroup-identical individuals
clustering together in a plot of PC1 and PC2. Subclades of
the same haplogroup (e.g., H1 and H2) also clustered in the
same region of the MDS plot, as did haplogroups de-
scended from a common precursor (e.g., J and T, or K, U,
WX, and I). Plotting the third PC from the mitochondrial
PCA (Figures 3C and 3D) further resolved and separated
these tightly clustered haplogroups.
Following up on qualitative exploration of the relation-
ship betweenmtPCs and haplogroups via visual inspectionGenetics 86, 904–917, June 11, 2010 909
Figure 2. Autosomal Population Struc-
ture and Mitochondrial Haplogroups in
the MGH-AIS Cohort
(A) Autosomal population structure as rep-
resented by plotting autosomal PCs 1 and 2
and corresponding individual mitochon-
drial haplogroup assignment in the MGH-
AIS cohort. Mitochondrial haplogroups
clearly distinguish individuals of Asian
and African ancestry from European Amer-
ican individuals, but they fail to correctly
identify Mexican American individuals
(identiﬁed as Asian haplogroup carriers).
(B) Autosomal population structure and
mitochondrial haplogroup assignment in
the EuropeanAmericanMGH-AIS subjects.
No intracontinental distribution of hap-
logroups is discernible within the Euro-
pean-ancestry cluster. Autosomal PCA was
performed separately after the removal of
individuals of non-European ancestry.of PCA output, we sought to quantify the correlation
between PCs and haplogroups. Our analyses uncovered
that all ten extracted mtPCs derived were associated with
haplogroup assignment (median correlation coefﬁcient:
0.87, range: 0.62–0.93, all p values < 0.001).
Limited Correlation between Mitochondrial
and Autosomal PCAs
We assessed associations between mitochondrial and auto-
somal population structure in individuals of European
ancestry by correlating nuclear PCs and mtPCs from the
two analyses. Given the strong association between auto-
somal population structure and geography, both within
and across continents,12,18 we were interested in identi-
fying patterns of covariance as signatures of PS. We identi-
ﬁed very limited correlation between mitochondrial and
autosomal PCs in MGH-AIS (correlation coefﬁcient range:
0.09 to 0.15, all p values > 0.05), MGH-ICH (correlation
range:0.09 to 0.014, all p values> 0.05), and ISGS-SWISS
(correlation range: 0.06 to 0.14, all p values > 0.05)
(Figure 4).
Given the known correlation between autosomal PCs
and geographical origin in European and European Amer-
ican populations,12,22 we hypothesized that only limited
correlation exists between mitochondrial population
structure and geographical genetic ancestry (i.e., geograph-
ical origin of ancestors within Europe) in our European
American cohort. Non-US European populations have
not experienced the same degree of admixture as that of
North American ones. Similarly, ethnic groups within
other continents might have experienced lower admixture
than European-ancestry US populations. A stronger rela-
tionship between autosomal and mitochondrial popula-
tion structure might therefore be present, based on
a similar correlation with geography.
In order to test this hypothesis, we performed a similar
analysis on autosomal and mitochondrial SNP data from
participants in the HGDP, separately correlating autosomal
and mitochondrial PCs for individuals enrolled within910 The American Journal of Human Genetics 86, 904–917, June 11,each continent. Correlation factors between autosomal
and mtPCs 1–5 were in fact higher in HGDP populations
(correlation coefﬁcient range: 0.38 to 0.26, Figure 4).Simulation of Mitochondrial Stratiﬁed Phenotypes
To quantify the effect of PS on mitochondrial genetic-
association analyses, we generated simulated case-control
and QTL phenotypes at different levels of association
with mtPC1 (10,000 iterations for each analysis). We
then computed mtGIFs without any adjustment for
population structure. We observed a wide range of mtGIFs
for case-control simulated phenotypes, from 1.2 (95%
conﬁdence interval [CI]: 1.0–1.3) for uncorrelated pheno-
types to 2.8 (95% CI: 2.7 –3.0) for strongly correlated
phenotypes (correlation coefﬁcient: 0.60). MtGIF for QTL
phenotypes ranged from an average of 1.1 (95% CI:
0.99–1.25) for nonstratiﬁed phenotypes to 2.6 (95% CI:
2.5–2.8) for phenotypes strongly correlated with PC1
(correlation coefﬁcient: 0.60). Observed mtGIF distribu-
tions for case-control and QTL simulations under different
parameters are presented in Figure S1.Controlling for PS in Mitochondrial Medical Genetics
On the basis of our analysis of mitochondrial population
structure, we next hypothesized that haplogroup informa-
tion would be crucial in controlling for confounding due
to PS for association studies of common mitochondrial
variants. We therefore evaluated the performance of
haplogroup-stratiﬁed analyses in minimizing genomic
inﬂation. Having observed that mitochondrial PCA reca-
pitulates haplogroup information, we also assessed perfor-
mance of PCA in PS control. We ﬁrst simulated 10,000
case-control phenotypes stratiﬁed according to varying
degrees of association with mtPC1. Logistic-regression
analyses of each phenotype (adjusted for age and gender)
were performed separately, both adjusting by haplogroups
(using all three procedures detailed in Subjects and
Methods) and after introduction of mtPCs.2010
Figure 3. Mitochondrial Population Structure in MGH-AIS
(A) Relationship between European mitochondrial haplogroups. Different colors identify haplogroups descending from the same
ancestral haplogroup (preHV ¼ green, JT ¼ light blue, N ¼ orange).
(B) mtPCs 1 and 2 recapitulate haplogroup information in European Americans enrolled in the MGH-AIS. Colored contours identify
haplogroups as in (A). Colored dots convey information about haplogroup assignment for each individual.
(C) Plotting mtPCs 1 and 3 further separates haplogroups K, I, and WX from U as compared to the plot in (B). Colored dots convey
information about haplogroup assignment for each individual as in (B).
(D) Tridimensional plot of mtPCs 1–3 in European Americans enrolled in MGH-AIS assigns individuals to clusters that recapitulate
mitochondrial haplogroup assignment.Mitochondrial PCA was more effective than haplogroup
stratiﬁcation in controlling mtGIF for analysis of case-
control and QTL phenotypes that are confounded bymito-
chondrial PS.We observed signiﬁcantly (p¼ 0.001) smaller
mtGIF values for PCA-adjusted analyses (median: 1.00, 95%
CI: 0.99–1.02) in comparison with haplogroup-adjusted
results (median: 1.8, 95% CI: 1.4–2.0) in MGH-AIS. We
obtained similar results in MGH-ICH (PCA mtGIF: median
1.01, 95%CI: 1.00–1.02; haplogroup mtGIF: median 1.6,
95% CI: 1.45–1.82; comparison p ¼ 0.0021) and ISGS-
SWISS (PCA mtGIF—median: 1.00, 95%CI: 1.00–1.01;
haplogroup mtGIF—median: 1.55, 95% CI: 1.30–1.64;The Amecomparisonp¼ 0.002). A signiﬁcant degree ofmetaanalysis
heterogeneity between haplogroups was identiﬁed when
thehaplogroup-stratiﬁcationmethodwas used: themedian
heterogeneity p value across all three data sets was 0.01
(95% CI: 0.008–0.02), and the median I2 (between-study
heterogeneity in effect sizes; I2 > 20% represents a signiﬁ-
cant degree of heterogeneity) was 0.32 (95% CI: 0.17–
0.48). Additional analyses using haplogroup-based strata
or haplogroup assignment as a categorical covariate also
showed signiﬁcantly higher mtGIFs (data not shown).
A similar analysis was carried out on 10,000 simulated
QTL phenotypes, again exhibiting varying degrees ofrican Journal of Human Genetics 86, 904–917, June 11, 2010 911
Figure 4. Correlation Coefficients for Autosomal PCs and mtPCs
Correlation between autosomal PCs and mtPCs is visualized as the distribution of correlation coefﬁcients (absolute values) for each
population enrolled in the participating studies. HGDP, Human Genome Diversity Panel; MGH-AIS, Massachusetts General Hospital
Ischemic Stroke Study; MGH-ICH, Massachusetts General Hospital Intracerebral Hemorrhage Study; ISGS, Ischemic Stroke Genetics
Study; SWISS, Siblings With Ischemic Stroke Studyassociation with mtPC1. We again observed signiﬁcantly
(p ¼ 0.01) lower mtGIF for PCA-adjusted analyses (median
mtGIF: 0.99, 95% CI: 0.98–1.01) as compared to meta-
analyses of haplogroup-stratiﬁed results (median mtGIF:
1.5, 95% CI: 1.4–1.9). We obtained similar results in
MGH-ICH (PCA mtGIF—median: 1.00, 95%CI: 0.99–
1.02; haplogroup mtGIF—median: 1.35, 95% CI: 1.15–
1.43; comparison p ¼ 0.009) and ISGS-SWISS (PCA
mtGIF—median: 1.02, 95% CI: 1.01–1.04; haplogroup
mtGIF—median: 1.75, 95% CI: 1.56–1.83; comparison
p ¼ 0.001). Across all three data sets, the median heteroge-
neity p value in QTL analyses for haplogroup-based adjust-
ment was 0.04 (95% CI: 0.02–0.10), and the median I2 was
0.23 (95% CI: 0.11–0.36). Similar results were obtained for
haplogroup-stratiﬁed analyses or with the use of hap-
logroup assignment as a categorical covariate (data not
shown).
To test the robustness of these ﬁndings, we reran all
simulations by generating a phenotype associated with
mitochondrial haplogroups. For case-control analyses
across all three data sets, PCA adjustment yielded signiﬁ-
cantly (p ¼ 0.022) lower mtGIFs (median: 1.01, 95% CI:
1.00–1.03) as compared to haplogroup-based adjustment
(median mtGIF: 1.32, 95% CI: 1.15–1.46). For QTL anal-
yses, PCA yielded signiﬁcantly (p ¼ 0.013) lower mtGIFs
(median mtGIF: 1.00, 95% CI: 0.99–1.02) as compared to
haplogroup-based adjustment (median mtGIF: 1.28, 95%
CI: 1.09–1.45).
In order to determine why haplogroup-based adjust-
ment for PS of simulated phenotypes stratiﬁed according
to haplogroup assignment yielded such inﬂated mtGIF
distributions, we tested the heterogeneity of the effect sizes
across haplogroups. Between-haplogroup effect-size
heterogeneity was elevated in both case-control (median912 The American Journal of Human Genetics 86, 904–917, June 11,heterogeneity p value: 0.05, 95% CI: 0.03–0.11; median
I2: 0.22, 95% CI: 0.16–0.31) and QTL (median heteroge-
neity p value: 0.07, 95% CI: 0.04–0.12; median I2: 0.19,
95% CI: 0.13–0.26) simulations. These ﬁndings reﬂect
systematic inconsistency in effect-size estimates across
haplogroups. When we repeated these analyses using
haplogroup-stratiﬁed adjustment or using haplogroup
assignment as a categorical covariate, we obtained similar
results (data not shown).
These results are notable in that they reveal a limited
correlation between test statistics obtained with the use
of different methods for controlling for confounding due
to PS. Concordance analysis for case-control test statistics
(mitochondrial PCA versus haplogroup stratiﬁcation)
across all three data sets returned a mean correlation
coefﬁcient of 0.41 (95% CI: 0.35–0.46, all p values >
0.05). Analysis of QTL phenotypes showed similar results,
with a mean correlation coefﬁcient of 0.52 (95% CI: 0.48–
0.57, all p values > 0.05).
We also assessed the effect of incorporating autosomal
PCs along with mtPCs when analyzing simulated pheno-
types associated with mtPC1. Comparing test statistics
obtained from analysis including and excluding autosomal
PCs 1–5, we observed a high degree of correlation for both
case-control and QTL simulations (mean correlation coefﬁ-
cient 0.99, 95% CI: 0.98–0.99), with no signiﬁcant differ-
ence in mtGIF (p ¼ 0.41). Even in the HGDP data sets,
despite the higher correlation between mitochondrial
and autosomal PCs, the autosomal population structure
information did not alter test statistics (mean correlation
coefﬁcient: 0.99, 95% CI: 0.97–0.99) or modify mtGIF
distribution (median mtGIF for mitochondrial PCA: 1.00,
95% CI: 0.98–1.02; median mtGIF for combined mito-
chondrial-autosomal PCA: 1.00, 95% CI: 0.98–1.01;2010
p¼ 0.72 for comparison of distributions). Incorporation of
autosomal population structure therefore appears to offer
little improvement in the efﬁciency or effectiveness of
mitochondrial PCA in controlling for confounding due
to mitochondrial PS.
Autosomal PS Does Not Impact Mitochondrial
Association Testing
In order to assess the effect of autosomal PS on mitochon-
drial association testing, we generated 10,000 simulated
stratiﬁed case-control phenotypes displaying varying
degrees of correlation with autosomal PC1. We subse-
quently examined the effect of this confounding variable
on mitochondrial association testing. To this end, we
analyzed mitochondrial common variants both before
and after adjustment for autosomal PCs 1–5. Both analyses
used logistic-regression models adjusted for gender and
age.
Test statistics were compared across all 10,000 analyses
and found to be highly correlated in MGH-AIS (median
correlation coefﬁcient: 0.98, empirical 95% CI: 0.97–
0.99), MGH-ICH (median correlation coefﬁcient: 0.99,
empirical 95% CI: 0.98–0.99), and ISGS-SWISS (median
correlation coefﬁcient: 0.99, empirical 95% CI: 0.98–
0.99). We separately assessed the difference in mtGIF
values before and after adjustment for autosomal PCs.
There was little evidence of mitochondrial genomic inﬂa-
tion (MGH-AIS—median mtGIF: 1.08, 95% CI: 1.05–1.11;
MGH-ICH—median mtGIF: 1.03, 95% CI: 1.00–1.05;
ISGS-SWISS—median mtGIF: 1.06, 95% CI: 1.02–1.08),
and no difference was present after adjustment for auto-
somal PCs (p ¼ 0.38). Generating simulated phenotypes
stratiﬁed according to nuclear PCs 2–10 yielded similar
results (data not shown).
We then performed a similar analysis using 10,000
simulated QTL continuous phenotypes, stratiﬁed on the
basis of varying degrees of correlation with autosomal
PC1. These phenotypes were analyzed with the use of a
linear-regression model (adjusted for age and sex), both
before and after adjustment for autosomal PCs 1–5. Mito-
chondrial association analysis of the QTL phenotypes
confounded by autosomal PS was again not dependent
on adjustment for nuclear PCA. Concordance for the two
analyses across all three data sets was high (median corre-
lation coefﬁcient: 0.94, 95% empirical CI: 0.92–0.96)
across all levels of phenotype stratiﬁcation. Distribution
of mtGIFs did not reﬂect signiﬁcant inﬂation in all data
sets (MGH-AIS—median mtGIF: 1.08, 95% CI: 1.04–1.10;
MGH-ICH—median mtGIF: 1.06, 95% CI: 1.03–1.08;
ISGS-SWISS—median mtGIF: 1.06, 95% CI: 1.04–1.10),
andmtGIF distributionwas not altered by the introduction
of autosomal PCs (p ¼ 0.72). Generating simulated pheno-
types stratiﬁed according to nuclear PCs 2–10 yielded
similar results (data not shown).
In summary, neither case-control nor QTL phenotypes
exhibiting autosomal PS were affected by nuclear PCA
adjustment in mitochondrial association testing. EvenThe Amemore important, analysis of these autosomally stratiﬁed
phenotypes showed little evidence of mitochondrial
genomic inﬂation, thereby consistent with a lack of inﬂu-
ence of autosomal genetic structure on mitochondrial
association testing.
Comparison of Array-Based and Comprehensive
Genotyping for Mitochondrial PCA
Because mitochondrial PCA was most efﬁcient in control-
ling mitochondrial PS in the prior analysis, we next set
out to determine the sensitivity of mitochondrial PS
adjustment using data derived from different genotyping
platforms. We compared mtGIFs and test statistics for
case-control and QTL analyses of simulated phenotypes
stratiﬁed according to varying degrees of correlation with
mtPC1. For this analysis, we compared results after intro-
duction of mtPCs 1–5, obtained from PCA performed on
either commercially available genome-wide arrays (Affy-
metrix 6.0 and Illumina 610 Quad) or custom exhaustive
mitochondrial genotyping data.
We observed good correlation between these two
methods for both mtGIFs (correlation coefﬁcient: 0.93,
95% CI: 0.90–0.95, mtGIF range for array-based PCA:
0.99–1.01) and test statistics (correlation coefﬁcient: 0.89,
95% CI: 0.88–0.92). We performed a similar analysis
comparing Illumina 610-Quad mitochondrial SNPs from
the MGH-ICH and ISGS-SWISS cohorts and comprehen-
sive mitochondrial genotyping from these cohorts. We
again observed a good correlation between both mtGIFs
(correlation coefﬁcient: 0.90, 95% CI: 0.89–0.91, mtGIF
range for array-based PCA: 1.00–1.02) and test statistics
(correlation coefﬁcient: 0.87, 95% CI: 0.84–0.90).
Regardless of platform, correlation coefﬁcients were not
associated with increasing degrees of mitochondrial
phenotype stratiﬁcation; i.e., correlation between pheno-
type and mtPC1 (p ¼ 0.43). When directly the two
genome-wide platforms were directly compared (Affyme-
trix 6.0 and Illumina 610 Quad), there was no discernible
difference in their ability to control for mitochondrial PS
using the mitochondrial SNPs available on each platform
(p ¼ 0.21 for comparison of mtGIF distributions). Mito-
chondrial SNPs captured by commercially available
genome-wide platforms appear to be adequate for imple-
mentation of mitochondrial PCA for control of confound-
ing due to PS.
Statistical Power
Using a previously published21 simulation-based method,
we empirically calculated power for discovery of associa-
tions in case-control and QTL analyses using a combined
data set obtained from pooling mitochondrial genotype
data from MGH-AIS, MGH-ICH, and ISGS-SWISS. Calcula-
tions were performed at different effect sizes (case-control:
relative risk of 1.2, 1.5, and 2.0; QTL: 2.5%, 0.5%, and 1.0%
of total variance explained) and for different sample sizes
(case-control: 500, 1000, 1500, and 3000 case-control
pairs; QTL: 500, 1000, 1500, and 3000 individuals).rican Journal of Human Genetics 86, 904–917, June 11, 2010 913
Table 2. Statistical Power Calculation Results
Phenotype Sample Size Effect Size
Unadjusted
Analyses
Haplogroup-Based
Adjustment mtPCA Adjustment
Comparison
p Value
Case-Control 500 OR ¼ 1.2 0.03 (0.01–0.05) 0.03 (0.01–0.04) 0.03 (0.01–0.05) 0.87
OR ¼ 1.5 0.11 (0.08–0.13) 0.10 (0.08–0.14) 0.11 (0.09–0.12) 0.64
OR ¼ 2.0 0.33 (0.27–0.35) 0.34 (0.28–0.34) 0.32 (0.28–0.35) 0.71
Case-Control 1000 OR ¼ 1.2 0.04 (0.02–0.05) 0.04 (0.02–0.06) 0.05 (0.02–0.07) 0.44
OR ¼ 1.5 0.21 (0.18–0.23) 0.20 (0.18–0.220 0.21 (0.19–0.23) 0.27
OR ¼ 2.0 0.48 (0.46–0.51) 0.48 (0.45–0.53) 0.47 (0.45–0.51) 0.78
Case-Control 1500 OR ¼ 1.2 0.05 (0.04–0.07) 0.04 (0.03–0.06) 0.04 (0.03–0.07) 0.25
OR ¼ 1.5 0.27 (0.25–0.31) 0.27 (0.24–0.30) 0.26 (0.25–0.31) 0.89
OR ¼ 2.0 0.64 (0.58–0.69) 0.65 (0.58–0.70) 0.64 (0.58–0.69) 0.60
Case-Control 3000 OR ¼ 1.2 0.07 (0.05–0.10) 0.06 (0.05–0.09) 0.07 (0.05–0.10) 0.32
OR ¼ 1.5 0.41 (0.37–0.44) 0.41 (0.36–0.42) 0.42 (0.38–0.44) 0.24
OR ¼ 2.0 0.83 (0.77–0.88) 0.81 (0.75–0.87) 0.82 (0.77–0.86) 0.67
QTL 500 var. expl. ¼ 0.25% 0.01 (0.00–0.02) 0.01 (0.01–0.02) 0.01 (0.00–0.02) 0.31
var. expl. ¼ 0.50% 0.12 (0.07–0.15) 0.11 (0.08–0.14) 0.11 (0.07–0.14) 0.28
var. expl. ¼ 1.00% 0.22 (0.18–0.26) 0.22 (0.17–0.25) 0.23 (0.18–0.25) 0.78
QTL 1000 var. expl. ¼ 0.25% 0.03 (0.01–0.04) 0.02 (0.01–0.04) 0.03 (0.01–0.04) 0.81
var. expl. ¼ 0.50% 0.23 (0.17–0.28) 0.23 (0.17–0.29) 0.22 (0.16–0.27) 0.22
var. expl. ¼ 1.00% 0.48 (0.44–0.53) 0.47 (0.45–0.52) 0.49 (0.45–0.51) 0.48
QTL 1500 var. expl. ¼ 0.25% 0.07 (0.04–0.10) 0.07 (0.03–0.11) 0.06 (0.05–0.10) 0.43
var. expl. ¼ 0.50% 0.34 (0.28–0.37) 0.34 (0.27–0.36) 0.34 (0.28–0.35) 0.52
var. expl. ¼ 1.00% 0.64 (0.58–0.70) 0.64 (0.58–0.70) 0.64 (0.57–0.70) 0.99
QTL 3000 var. expl. ¼ 0.25% 0.32 (0.28–0.35) 0.30 (0.27–0.34) 0.32 (0.25–0.37) 0.42
var. expl. ¼ 0.50% 0.66 (0.59–0.72) 0.65 (0.57–0.71) 0.66 (0.60–0.71) 0.66
var. expl. ¼ 1.00% 0.92 (0.84–0.97) 0.93 (0.85–0.96) 0.91 (0.84–0.97) 0.56
For each simulation scenario, the average statistical power across the entire distribution of MAF for mitochondrial SNPs is shown, with interquartile ranges of
observed distributions in parentheses. Sample size refers to the number of case-control pairs (case-control setting) or of individuals with QTL data available
(QTL setting). Effect size is defined as odds ratio (case-control) or proportion of phenotypic variance explained (QTL). Empirical power estimates for different
adjustment methods were compared with an ANOVA. For haplogroup-based adjustment, the highest power estimate for all three analytical methods tested
(see Subjects and Methods) is reported. OR, odds ratio; var. expl., percentage of phenotypic variance explained; QTL, quantitative trait locus.Statistical signiﬁcance was determined at 5% experiment-
wide empirical signiﬁcance, and results for different
methods were compared.
In the case-control analysis, empirically determined
power was not different in a comparison of haplogroup-
based or mitochondrial PCA adjustments to the baseline
analysis (adjusted only for age and sex): all SNPs had
similar power for discovery of associations in a comparison
of the three methods (all p values > 0.05), and the average
mitochondrial-wide power was also not different among
all simulation scenarios (Table 2).
Similarly, we observed no differences in statistical power
for discovery of associations with QTL phenotypes. In
comparing to the baseline analysis (adjusted only for age
and sex), we observed no differences in power for both
the haplogroup-based and the mitochondrial PCA adjust-
ments (all p values for single-SNP analyses > 0.05). The914 The American Journal of Human Genetics 86, 904–917, June 11,average mitochondrial-wide statistical power for associa-
tion discovery was also not different (Table 2).Mitochondrial Stroke Genetics
To conﬁrm the utility of an efﬁcient and effective method
for PS control in mitochondrial medical genetics, we
analyzed data collected as part of the MGH-AIS (660 cases
and 749 controls of European American ancestry). We
observed an mtGIF of 2.46 for the case-control analysis
adjusted only for age and sex. Haplogroup-adjusted anal-
yses returned an mtGIF of 2.32, whereas adjustment using
PCs 1–5 from mitochondrial PCA returned an mtGIF of
0.99 (Figure 5). There was very limited correlation between
test statistics returned by the haplogroup-based adjust-
ment and those returned by the PCA-based adjustment
(correlation coefﬁcient: 0.48, p ¼ 0.56).2010
Figure 5. Comparison of Haplogroup-Based and PCA-Based Control for PS in the MGH Mitochondrial Stroke Genetics Study
Quantile-quantile plots for the mitochondrial GWAS of ischemic stroke in the MGH-AIS cohort and for corresponding mtGIF are shown
for analyses adjusted for PS with the use of either haplogroup-based or mitochondrial PCA-based methods.Control of mtPCA effectively removed a false-positive
association that emerged in ahaplogroup-adjusted analysis.
Upon analysis of data from the MGH-AIS cohort, one
variant surpassed the mitochondrial genome-wide signiﬁ-
cance threshold (Bonferroni correction for 144
independent tests) in the haplogroup-adjusted analysis
(odds ratio [OR]: 0.42, 95% CI: 0.23–0.78, uncorrected
p ¼ 1.9 3 105, Bonferroni-corrected p ¼ 0.00023).
PCA-adjusted analysis, however, yieldedno signiﬁcant asso-
ciation (OR:0.43, 95%CI: 0.23–0.80,uncorrectedp¼0.006,
Bonferroni-corrected p ¼ 0.87). When attempting replica-
tion of the observed association in the ISGS-SWISS data set
(602 cases and 444 controls), we found no association in
unadjusted (p ¼ 0.95), haplogroup-adjusted (p ¼ 0.94),
and PCA-adjusted (p ¼ 0.94) analyses, despite statistical
power for replication of 0.83 based on parameters from
the discovery data set (a ¼ 0.05, OR ¼ 0.42, MAF ¼ 0.02).
These results highlight the real-world importance of
adequate control for PS in mitochondrial association
studies, and they conﬁrm the effectiveness of mitochon-
drial PCA.
Discussion
Our analysis has demonstrated the potential effect of PS on
mitochondrial-genetics studies. We have presented a PCA-
based method that summarizes haplogroup information
and provides robust correction for PS, regardless of the
degree of confounding between phenotype and genotype
data. Although association analyses comparing hap-
logroup frequencies between cases and controls can
account for confounding due to PS, their ability to identify
speciﬁc disease-associated variants is limited. Our
PCA-based method represents an efﬁcient and effectiveThe Ameapproach that can identify disease associations for speciﬁc
SNPs. This PCA-based method appears to be superior to
haplogroup-adjusted analyses because it more efﬁciently
controlled inﬂation of association statistics for mitochon-
drial variants, as determined by mtGIFs. We have further
shown that correction for confounding by PS can be
attained without corresponding autosomal PCs and that
mitochondrial SNPs encoded on commercial GWAS
platforms can provide adequate information for the reca-
pitulation of PCA information obtained from comprehen-
sive genotyping.
Multiple prior studies in mitochondrial medical genetics
either have not addressed PS or have limited analysis to
speciﬁc haplogroups in an attempt to control for it. Our
data suggest that a minimal degree of inﬂation in signiﬁ-
cance for unadjusted analyses (as measured by the mtGIF)
is present even for phenotypes displaying no degree of
correlation with mitochondrial population structure.
This ﬁnding is most likely explained by the presence of
several SNPs with widely varying MAFs within each
haplogroup. Indeed, prior studies have also identiﬁed
this phenomenon in unrelated cohorts.29 These outliers
create inﬂated results based on differential assignment of
individuals to haplogroups.
Mitochondrial PCA controlled for PS more effectively
than haplogroup-based methods in our analyses. Indeed,
we were able to eliminate a false-positive association
that emerged from an initial analysis using a haplogroup-
based approach. This ﬁnding supports results from our
simulations, which demonstrated high heterogeneity in
effect-size estimates across haplogroup-deﬁned strata.
Haplogroup assignment thus appears to offer lower infor-
mation content for mitochondrial ancestry than does
PCA, which leverages linkage disequilibrium to utilizerican Journal of Human Genetics 86, 904–917, June 11, 2010 915
almost all information on common variation contained in
the mitochondrial genome.
In our analyses, the addition of information on auto-
somal population structure (in the form of PCs) did not
alter mitochondrial genetic-association tests, and it
provided no beneﬁt in controlling for mitochondrial PS.
This ﬁnding is consistent with our results on limited corre-
lation existing between nuclear and population structure
within European American populations, as determined
either by haplogroups or by PCs. Even analysis of non-US
populations with lower levels of intracontinental admix-
ture are unlikely to be able to rely solely on autosomal
PCA (or case-control geographic matching) for control of
confounding due to mitochondrial PS. Although we did
observe higher correlation between autosomal and mtPCs
in HGDP individuals, autosomal PCs did not affect the
mitochondrial analysis in this second data set or inﬂuence
mtGIF distribution.
In the evaluation of widely available methods for mito-
chondrial genotyping, we compared the efﬁciency of
PCA performed with the use of data from commercially
available genome-wide platforms and that performed
with the use of comprehensive genotyping data. Although
genome-wide arrays do not necessarily capture the entirety
of common genetic variation within the mitochondrial
genome, we observed good concordance between these
two strategies. This should allow merging of results from
arrays and comprehensive genotyping with the use of
the same PCA-based method for PS control. It should
also allow mitochondrial association testing to be per-
formed with the use of GWAS arrays, with a reasonable
degree of control for underlying population structure.
Our study has limitations. We used mtGIF to measure
the degree of inﬂation of results for mitochondrial associa-
tion studies. This metric, given the limited number of SNPs
being analyzed, is more sensitive to the inﬂuence of
outlying association values than to that of the correspond-
ing autosomal inﬂation factors for which the metric was
initially designed. The application of GIF to mitochondrial
association testing could be viewed as overly conservative,
particularly given the presence of minimal inﬂation even
for uncorrelated phenotypes. However, this phenomenon
reﬂects fundamental characteristics of the mitochondrial
genome, such as the uniparental inheritance and lack of
recombination, resulting in a generally stronger LD than
that found in the autosomal genome. These characteristics
explain the association between relatively fewmarkers and
population structure arising fromwide ﬂuctuations inMAF
across different haplogroups. These ﬂuctuations could
create spurious associations if not controlled. Another
limitation is that the majority of our results were generated
with the use of simulated phenotypes. Simulated pheno-
types allow the precise control of experimental conditions
for varying degrees of stratiﬁcation using either case-
control or QTL phenotypes. We were careful to perform
10,000 iterations of each stratiﬁed simulation in order to
exclude random ﬂuctuations from outlying data points.916 The American Journal of Human Genetics 86, 904–917, June 11,We also compared our in silico results to those obtained
with clinical data from mitochondrial association studies
of stroke, to ensure that our simulation-derived results
were consistent with actual medical-genetics data sets.
We excluded from analysis the limited number of samples
of non-European ancestry in our clinical data sets. Addi-
tional studies will be required to evaluate the effectiveness
and efﬁciency of mitochondrial PCA in non-European
individuals, as well as to conﬁrm that commercial arrays
represent a viable alternative to targeted genotyping for
other continental populations.
In summary, we present a PCA-based method for control
of confounding due to PS in mitochondrial medical-
genetics studies. This method, while highlighting the
importance of haplogroups in determining mitochondrial
population structure, is superior to haplogroup-based
methods in controlling for confounding by PS. This
PCA-based technique does not require autosomal geno-
type information in order to correctly adjust for mitochon-
drial population structure, but it is comparably effective if
using a genome-wide array or comprehensive genotyping
data as input. Future association studies in mitochondrial
medical genetics will likely beneﬁt from the application
of this method to control for PS.Supplemental Data
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